Log In

EDRN Catalog and Archive Service


nanoString multi-marker RNA digital counts

Dataset Abstract:

RNA transcripts from cell types found in urine are measured by nCounter analysis. Counts of markers associated with prostate cancer cell types are indicative of cancer presence. This is a multiplex assay to score the abundance of multiple informative (RNA) biomarkers in urine. Urine analysis is the least invasive and multiple donations can be obtained.


The following additional information has been defined for this dataset. The information has been provided by the Principal Investigator or staff from his or her laboratory.

ProtocolId
114
ProtocolName
DataSetName
nanoString multi-marker RNA digital counts
LeadPI
Alvin Liu
SiteName
DataCustodian
Alvin Liu
DataCustodianEmail
aliu@u.washington.edu
OrganSite
Bladder
Prostate
CollaborativeGroup
Prostate and Urologic
MethodDetails
Voided urine samples are centrifuged, cells in the pellet are lysed for nucleic acid, RNA is amplified via in vitro transcription, amplified RNA is hybridized to the nCounter codeset (designed for specific application – detection of prostate cancer)
Date
2013-01-08T13:18:53.224Z
QAState
Accepted
LeadPI_fullname
Alvin Liu
DataDisclaimer
Data and information released from the National Cancer Institute (NCI) are provided on an "AS IS" basis, without warranty of any kind, including without limitation the warranties of merchantability, fitness for a particular purpose and non-infringement. Availability of this data and information does not constitute scientific publication. Data and/or information may contain errors or be incomplete. NCI and its employees make no representation or warranty, express or implied, including without limitation any warranties of merchantability or fitness for a particular purpose or warranties as to the identity or ownership of data or information, the quality, accuracy or completeness of data or information, or that the use of such data or information will not infringe any patent, intellectual property or proprietary rights of any party. NCI shall not be liable for any claim for any loss, harm, illness or other damage or injury arising from access to or use of data or information, including without limitation any direct, indirect, incidental, exemplary, special or consequential damages, even if advised of the possibility of such damages. In accordance with scientific standards, appropriate acknowledgment of NCI should be made in any publications or other disclosures concerning data or information made available by NCI.